In a prospective cohort study by Odén et al., the authors showed that high vs. low plasma OPG was associated with risk of developing breast cancer among BRCA1 and BRCA2 mutation carriers (n = 206; HR = 0.25; 95% CI 0.08–0.78; p = 0.02) [44]. This evidence concerns the gene BRCA2 and breast carcinoma.